Grail's multi-cancer test fluffs its lines in UK trial Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

Just weeks after filing for #FDA approval of its #Galleribloodtest for #cancerscreening, #Grail has reported that a flagship trial of the technology in the UK failed to achieve its primary objective.